GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arcadia Biosciences RKDA · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.17

+2.98%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Arcadia Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Arcadia Biosciences is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RKDA. The SEC classifies its business as crude petroleum & natural gas. In the fiscal year to 31 December 2025, it reported revenue of $4.9m and a net loss of $2.3m. At that date it held total assets of $6.5m.

In its own words

Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Since acquiring the assets of Zola in May 2021, Arcadia has provided consumers with a way to rehydrate, reset, and reenergize with Zola coconut water products. Previously, Arcadia developed products, primarily in wheat, which it commercialized through the sale of food products, trait licensing and royalty agreements.

On December 4, 2024, Arcadia, Roosevelt Resources LP (“Roosevelt” or the “Partnership”) and Elliott Roosevelt, Jr. and David A. Roosevelt, in their capacities as representatives of the limited partners of the Partnership entered into a Securities Exchange Agreement (as it may be amended from time to time, the “Exchange Agreement”) providing for the combination of the two companies in an all-stock transaction. Subject to the terms of the Exchange Agreement and to the satisfaction or waiver of the conditions set forth in the Exchange Agreement, at the closing of the transactions Arcadia agreed to issue shares of its common stock to the limited partners and to the sole member of the general partner of Roosevelt (together, the “Limited Partners”) in exchange for all of the limited partnership and other equity interests of Roosevelt (the “Exchange”). The Exchange Agreement, as amended, provided that upon completion of the Exchange, the Limited Partners and the Arcadia stockholders prior to the closing were to own 90% and 10%, respectively, of the shares of common stock of Arcadia immediately after the closing.

Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Consumer Staples
Industry
Food Products
Listed since
15 May 2015
Employees
8
Head office
5956 SHERRY LANE, DALLAS, TX
Incorporated in
DE
Classification
Crude Petroleum & Natural Gas
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Kevin ComcowichIndependent Chairman of the Board, since 2016$153,442
  • Mr. Thomas SchaeferPresident, Chief Executive Officer, Interim Chief Financial Officer, since 2023$499,477
  • Ms. Lilian MurrayIndependent Director$92,474
  • Mr. Gregory WallerIndependent Director$90,974
  • Ms. Amy YoderIndependent Director$88,974

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Arcadia Biosciences develops nitrogen use efficiency traits for global crops like wheat and rice.
  • The company has a pipeline of products in advanced development stages for food and feed markets.
  • Arcadia's portfolio includes drought tolerance and salinity tolerance traits for crops in Africa and India.

Weaknesses

  • Arcadia employs only 8 full-time employees, which is below the industry standard for biotech firms.
  • The company's headquarters in Davis, California, limits its operational scale compared to larger competitors.
  • Arcadia's IPO in 2015 has not led to significant market expansion or product launches.

Opportunities

  • Arcadia can expand its presence in the United Arab Emirates and Canada for agricultural product distribution.
  • The growing demand for water use efficiency traits in drought-prone regions offers new market opportunities.
  • India's agricultural sector presents a significant opportunity for deploying salinity tolerance traits.

Threats

  • Competition from larger biotech firms in the United States poses a threat to Arcadia's market share.
  • The lack of a strong product portfolio in the European market increases vulnerability to regional competitors.
  • Regulatory changes in the Food Products sector could impact Arcadia's trait development and market entry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.